Rizatriptan benzoate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1998
- First approval year
- 1998
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Rizatriptan benzoate
- Molecular weight
- 391.48
- Structure (SMILES)
- CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1
- maxalt
- Maxalt
- maxalt mlt
- Maxalt-mlt
- rizafilm
- Rizafilm
- rizatriptan benzoate
- Rizatriptan benzoate
- maxalt 10mg mlt
- Maxalt 10mg MLT
- mk 0462
- MK-0462
- nsc 758919
- NSC-758919
- rizafilm
- Rizafilm
- rizatriptan benzoate
- Rizatriptan benzoate
- Rizatriptan Benzoate
- rizatriptan benzoate (MK0462)
- RIZATRIPTAN BENZOATE [EP MONOGRAPH]
- RIZATRIPTAN BENZOATE [JAN]
- RIZATRIPTAN BENZOATE [MART.]
- RIZATRIPTAN BENZOATE [MI]
- RIZATRIPTAN BENZOATE [ORANGE BOOK]
- RIZATRIPTAN BENZOATE [USAN]
- RIZATRIPTAN BENZOATE [USP MONOGRAPH]
- RIZATRIPTAN BENZOATE [USP-RS]
- RIZATRIPTAN BENZOATE [VANDF]
- Rizatriptan benzoate [WHO-DD]
- rizatriptan benzoate 10 mg
- rizatriptan benzoate 5 mg
- rizatriptan benzoate ep monograph
And 12 more, listed on the interactive page.
- CAS registry numbers
- 145202-66-0
- ChEMBL ID
- CHEMBL1201032
- InChIKey
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 237082
- FDA ingredient codes (UNII)
- WR978S7QHH
- 77997
- 68473071
- Applicant
- ORGANON LLC
- Approval date
- 29 Jun 1998
- Application number
- NDA020864
- Patents
- 1
- Designations
- 0
- Earliest recorded loss of exclusivity
- 30 Jul 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- rizatriptan
- Type
- Synthetic organic
- Drug name stem
- -triptan
Administration routes
- Oral
- Mechanism
- Serotonin 1b (5-HT1b) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1B
- Protein identifier
- P28222
- Mechanism
- Serotonin 1d (5-HT1d) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1D
- Protein identifier
- P28221
- Mechanism
- Serotonin 1b (5-HT1b) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1B
- Mechanism
- Serotonin 1d (5-HT1d) receptor agonist
- Action type
- Agonist
- Target
- 5-hydroxytryptamine receptor 1D
- Condition
- Migraine Disorders
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition
- Migraine with Aura
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005475
- Subject identifier
- D020325
- Condition
- Migraine without Aura
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100431
- Subject identifier
- D020326
- Condition identifier
- MONDO_0005277
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005475
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100431
- Highest recorded phase
- 3
Warnings
- Warning
- Black Box Warning
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- abdominal pain
- Reports
- 36
- Reporting signal score
- 12.9843
- Event
- abdominal pain upper
- Reports
- 27
- Reporting signal score
- 13.4301
- Event
- acute respiratory failure
- Reports
- 12
- Reporting signal score
- 20.2922
- Event
- alanine aminotransferase increased
- Reports
- 22
- Reporting signal score
- 14.3632
- Event
- anuria
- Reports
- 13
- Reporting signal score
- 27.8633
- Event
- aspartate aminotransferase increased
- Reports
- 21
- Reporting signal score
- 14.8521
- Event
- atheroembolism
- Reports
- 3
- Reporting signal score
- 13.4378
- Event
- blood chloride decreased
- Reports
- 6
- Reporting signal score
- 13.6439
- Event
- broad ligament tear
- Reports
- 3
- Reporting signal score
- 21.9256
- Event
- carotid artery dissection
- Reports
- 7
- Reporting signal score
- 29.417
- Event
- chest discomfort
- Reports
- 27
- Reporting signal score
- 22.4586
- Event
- chest pain
- Reports
- 32
- Reporting signal score
- 15.5779
- Event
- colitis ischaemic
- Reports
- 27
- Reporting signal score
- 81.4397
- Event
- coronary artery dissection
- Reports
- 10
- Reporting signal score
- 40.0367
- Event
- cough
- Reports
- 38
- Reporting signal score
- 16.2122
- Event
- drug abuse
- Reports
- 24
- Reporting signal score
- 24.0348
- Event
- drug hypersensitivity
- Reports
- 48
- Reporting signal score
- 21.9553
- Event
- drug interaction
- Reports
- 47
- Reporting signal score
- 27.9695
- Event
- duodenal ulcer
- Reports
- 8
- Reporting signal score
- 12.7222
- Event
- extrapyramidal disorder
- Reports
- 13
- Reporting signal score
- 19.3264
- Event
- gallbladder polyp
- Reports
- 14
- Reporting signal score
- 65.7329
- Event
- gastritis
- Reports
- 13
- Reporting signal score
- 15.7596
- Event
- gastroenteritis radiation
- Reports
- 5
- Reporting signal score
- 20.9084
- Event
- glaucoma
- Reports
- 9
- Reporting signal score
- 12.9947
- Event
- granulosa cell tumour of the testis
- Reports
- 2
- Reporting signal score
- 14.3805
And 42 more, listed on the interactive page.
- NCT00092963
- NCT00095004
- NCT00111709
- NCT00111722
- NCT00516737
- NCT00604812
- NCT00719134
- NCT00753311
- NCT00812006
- NCT00897104
- NCT00897949
- NCT00898677
- NCT00899379
- NCT01004263
- NCT04384367
- NCT06473597
- NCT00471952
- Dose
- 5-10 mg
- Route
- Oral
- How often
- As needed
- Do not exceed 30 mg in 24 hours
- Single 5 mg dose in patients on propranolol weighing 40 kg or more
- Up to 3 doses in 24 hours in adult patients taking propranolol
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 49.74
- Calculated partition coefficient (ALogP)
- 1.91
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 29
- Molecular formula
- C22H25N5O2
- Monoisotopic mass
- 391.20082506
- Natural product
- No
- 0093-7471
- 0093-7472
- 29300-268
- 29300-269
- 29300-316
- 29300-317
- 33342-087
- 33342-088
- 33342-093
- 33342-094
- 43817-133
- 43817-135
- 51407-679
- 51407-680
- 51407-681
- 51407-682
- 57237-085
- 57237-086
- 57237-087
- 57237-088
- 61919-394
- 61919-656
- 65862-599
- 65862-600
- 65862-625
And 46 more, listed on the interactive page.
- Recorded assays
- 431
- Active assays
- 1
Active assay types
- Screening
- Serotonin Receptor Agonists
Related records
Trials (15)
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
- A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
- Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
- MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
- Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
- The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
- Treatment of Multiple Attacks of Acute Migraine (0462-025)
Approved for (1)
In development for (2)
- Migraine with aura Phase 3
- Migraine without aura Phase 3